Early detection is one of the most critical performance characteristics of modern HIV diagnostic assays. To accurately evaluate analytical sensitivity and determine how early an infection can be detected, developers rely on high-quality, well-characterized seroconversion panels.
Recent peer-reviewed studies demonstrate how BIOMEX HIV seroconversion panels have supported the development and validation of HIV assays by enabling:
- Assessment of analytical sensitivity
- Evaluation of early seroconversion detection
- Detection window analysis
- Clinical performance validation
Particularly during the earliest stages of HIV infection, well-characterized seroconversion panels provide an essential reference for determining assay sensitivity and ensuring reliable performance. The quality of the panel directly influences the ability to evaluate how early an assay can detect infection and to compare performance across different technologies and platforms.
With decades of experience in human biospecimen collection and characterization, BIOMEX provides HIV seroconversion panels that support assay development, analytical performance evaluation and clinical validation. Our panels are trusted by diagnostic developers worldwide and have been referenced in multiple peer-reviewed scientific publications.
Related Publications
Explore recent publications featuring BIOMEX HIV seroconversion panels:
